Healthcare Professionals
ALLURION PROGRAM
The world's only gastric
balloon-based program with no endoscopy, anesthesia or surgery**
- 150,000 balloons placed
- Offered in 80+ countries
- Placed during a 20-minute outpatient visit1
- 10 to 15% total body weight loss4*
The future of weight loss
The Allurion Program is a holistic weight-loss program centered around the world's first and only gastric balloon that does not require surgery, endoscopy or anesthesia.** It is combined with the behavior change support to help your clinic team deliver extremely effective results for patients.
The Allurion Program is addressing the unmet needs of your patients.
ALLURION BALLOON
How it works
The balloon is packaged into a capsule that is easily swallowed by the patient during a 20-minute visit. 99.9% of the patients can swallow it.1
The Allurion Balloon is made of polyurethane and crafted to adapt to the shape of the patient's stomach. It is filled with 550ml of liquid.
After approximately 16 weeks, the Allurion Balloon's release valve automatically opens, allowing the balloon to empty and pass naturally.**
CLINICAL STUDIES
Quick, safe and effective
The Allurion Balloon is a liquid-filled gastric balloon placed without endoscopy or anesthesia during a 20-minute outpatient visit.1,4 It empties itself after approximately 16 weeks and is eliminated naturally**. More than 150,000 balloons have been placed globally with an adverse event rate of <2% and a serious adverse event rate of <0.2%.6
Multiple studies have demonstrated an average body weight loss of 10-15%*. Furthermore, 96% of weight loss is maintained after one year7. You can find literature below for more information.
The Allurion Balloon is used in conjunction with a supervised nutrition and behavior modification program for at least 6 months. Allurion also provides the Allurion Virtual Care Suite, a patient management platform to help you monitor your patients' progress and offer personalized support.
ALLURION VIRTUAL CARE SUITE
Smart patient monitoring
A key component of the Allurion Program, the Allurion Virtual Care Suite is a dynamic weight-loss management suite powered by artificial intelligence and designed to maximize your patient outcomes and satisfaction. Remote patient monitoring, telehealth and care team collaboration - all under the one digital umbrella.
BEING AN ALLURION PARTNER
Dedicated support from Allurion
Get support from day 1
Place your first 10 balloons with the support of the Allurion team.
Leverage in-clinic marketing tools.
Get support to help create your multidisciplinary Allurion Program.
Benefit from our expertise
Get access to our clinical expertise and market research.
Participate in the Allurion Academy, a workshop series accredited by SCOPE, the only internationally recognized certification in obesity management.
Benefit from online advertising and marketing rewards.
Increase patient engagement and satisfaction
Get access to the Allurion Virtual Care Suite to manage your patients.
Allurion Assurance Plus Warranty included.
HEAR FROM OTHER PROFESSIONALS
Trusted by world-class clinics
Become an Allurion Partner
*Results may vary from one patient to another. The average of 14.2% (+/- 5%) was demonstrated by a clinical study conducted on 1,770 patients with an average BMI of 34.4 ± 5.3 kg/m² (1).
**The removal of the Allurion Balloon may, in very rare cases, require an endoscopic or surgical procedure. In rare cases, instead of being passed through the digestive tract, the deflated balloon may be expelled by vomiting.
***Eligibility for the placement of an Allurion Balloon will be assessed by a certified doctor after an initial consultation and a thorough review of your medical history. In the case of an extended Allurion Programme, your eligibility will be reassessed before each placement to ensure that you continue to meet the required conditions.
1. R. Ienca et al. The procedureless Elipse gastric balloon program: Multicenter experience in 1,770 consecutive patients. Obes Surg. 2020;30(9):3354-3362.
A multicentre, prospective, non-randomised, open registry study conducted on overweight or obese patients from January 2016 to June 2019 across 19 international obesity centres participating in the study. A total of 1,770 patients with an average BMI of 34.4 ± 5.3 kg/m² at baseline underwent treatment with the Elipse swallowable gastric balloon, with monthly visits and a total follow-up of 4 months. 63 patients (3.6%) did not complete the programme, and the balloon was removed before 4 months due to intolerance or other adverse effects.
2. World Health Organization - Key facts about obesity and overweight (who.int).
4. This information is extracted from the device's leaflet - Instructions for use - Allurion Gastric Balloon - CS137-02-ENG-ART. If you have any further questions regarding this document, please consult your doctor.
5. Allurion consumer market research: 9,800 respondents, 8 geographies, Oct. 2018.
6. Data from Jan 2016 – Jan 2024, Allurion Post Market Vigilance Reports.
7. Ienca R et al. Presented at EASO 2022
Retrospective study conducted on 522 patients living with overweight or obesity with a mean BMI of 35.9 ± 5.8 kg/m² at inclusion, who underwent treatment with the Allurion Gastric Balloon, with monthly follow-up during the time the balloon remained in the stomach and continued for 1 year after the balloon was eliminated.